4.4 Article

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients

期刊

CURRENT ONCOLOGY
卷 29, 期 6, 页码 4138-4147

出版社

MDPI
DOI: 10.3390/curroncol29060330

关键词

sunitinib; mean corpuscular volume; MCV; toxicity

类别

资金

  1. Ministry of Health, Czech Republic-Conceptual Development of Research Organization [MMCI 00209805, FNBr. 65269705]
  2. Ministry of Education, Youth and Sports, MEYS-Czech Clinical Research Infrastructure (CZECRIN) [LM2018128]
  3. BBMRI-CZ [LM2018125]
  4. specific university research Project [MUNI/A/1427/2021]

向作者/读者索取更多资源

This study retrospectively analyzed the data of adult and pediatric patients treated with sunitinib, and found that sunitinib treatment increased the mean corpuscular volume of erythrocytes. The study also found that the rate of increase was faster in patients who experienced treatment-related adverse events.
Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an off-label option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, p = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据